The time has unknowingly reached the end of the year, has the wish of 2019 been realized?Has the fund arrived?Have you passed the exam?Has the paper been published?Did the experiment have a positive result?Even if you answered “No” to all the above questions, don’t be sad. In 2019, something quite satisfactory will happen.For example: The first season of a large-scale academic battle series about the effectiveness of fish oil, which has been chasing after all, has finally come to an end in 2019.On December 13, the US Food and Drug Administration (FDA) approved Vascepa (this is a single-molecule prescription drug derived from fish oil, not fish oil itself!) As a target for elevated blood triglycerides (TG≥150 mg / dL)Adult applications for adjuvant statins and treatments that reduce the risk of cardiovascular events.The approval of this indication put an end to the long-lasting fish oil effectiveness battle (previously the drug was approved by the FDA in 2012 as an adjuvant treatment for severely high triglyceride in adults).Vascepa’s active ingredient is an omega-3 unsaturated fatty acid derived from fish oil called EPA. Dr. John Sharretts, Acting Executive Deputy Director of the Metabolic and Endocrine Products Division of the FDA’s Center for Drug Evaluation and Research, said: FDA recognizes Vascepa as a cardiovascular diseaseAs an additional treatment, the approval of this drug will add new adjuvant treatment options to patients with elevated triglyceride levels and those with heart disease, stroke, and diabetes, further reducing the risk of cardiovascular events based on statin medication.As of now, the specific pharmacological mechanism of Vascepa in reducing the risk of cardiovascular events is not clear, but its REDUCE-IT study based on its market confirms its safety and effectiveness: The study recruited a total of 8179 subjects from 11 countries around the world.The subjects included patients over 45 years of age who had a history of cardiovascular and cerebrovascular disease, and carotid and peripheral arterial disease, as well as those who were 50 years of age and over who had diabetes and other cardiovascular risk factors.Studies show that in the intention-to-treat population, the relative risk of first major adverse cardiovascular events (MACE) is further reduced by 25% (HR 0.75; 95% CI: 0.68-0.83; p <.0.001).The key secondary endpoint (complex endpoint of cardiovascular death, nonfatal MI, and nonfatal stroke) had a 26% reduction in relative risk of events (HR 0.74; 95% CI: 0.65-0.83; p <0.001).Other secondary endpoints include: a 20% reduction in the risk of cardiovascular death, a 31% reduction in the risk of fatal or non-fatal MI, a 28% reduction in the risk of fatal or non-fatal stroke, and a reduced risk of acute or emergency coronary revascularization35%, and the risk of hospitalization for unstable angina pectoris decreased by 32%.However, it should be noted that it is absolutely impossible to achieve satisfactory blood lipid control through medication alone, and lifestyle changes such as healthy diet and physical exercise are also indispensable.The FDA also recommends that patients receiving Vascepa must also co-exist with cardiovascular disease / diabetes, and that there are two or more additional risk factors for cardiovascular disease.Koi has something to say and summarize in one sentence: EPA, a fish oil extract, can indeed help reduce lipids, but it must be used in large doses and on the basis of statin therapy. Patients must co-exist with cardiovascular disease / diabetes and have two or moreAdditional risk factors for cardiovascular disease.Fish oil is effective. The first season ends in this way. Are you satisfied with the results?